Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugues Dolgos

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Drug Discovery Today|January 24, 2009
Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerationsJohan Gabrielsson, Hugues Dolgos, Per-Göran Gillberg, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 21, 2009
In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactionsRoslyn S Thelingwani, Simbarashe P Zvada, Hugues Dolgos, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 12, 2010
In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibitionDieter Gallemann, Elmar Wimmer, Constance C Höfer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 3, 2014
Time- and NADPH-dependent inhibition of cytochrome P450 3A4 by the cyclopentapeptide cilengitide: significance of the guanidine group and accompanying spectral changesMirza Bojić, Luca Barbero, Hugues Dolgos, et al.
Pharmacology Research & Perspectives|April 13, 2016
In vitro and in vivo drug disposition of cilengitide in animals and humanHugues Dolgos, Achim Freisleben, Elmar Wimmer, et al.
Clinical Pharmacology and Therapeutics|October 15, 2019
Evaluating the Role of Solubility in Oral Absorption of Poorly Water-Soluble Drugs Using Physiologically-Based Pharmacokinetic ModelingChristina Fink, Dajun Sun, Knut Wagner, et al.
Drug Metabolism Reviews|June 16, 2012
The right compound in the right assay at the right time: an integrated discovery DMPK strategyPeter Ballard, Patrick Brassil, Khanh H Bui, et al.
Drug Discovery Today|January 19, 2016
Translational Medicine Guide transforms drug development processes: the recent Merck experienceHugues Dolgos, Mark Trusheim, Dietmar Gross, et al.
Drug Discovery Today|April 7, 2020
Translational strategies in drug development for knee osteoarthritisKyra J Cowan, Kerstin Kleinschmidt-Dörr, Anne Gigout, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 13, 2018
A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug EvofosfamideChristian Lüpfert, Martin Dyroff, Oliver von Richter, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Drug Discovery Today|January 24, 2009
Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerationsJohan Gabrielsson, Hugues Dolgos, Per-Göran Gillberg, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 21, 2009
In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactionsRoslyn S Thelingwani, Simbarashe P Zvada, Hugues Dolgos, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 12, 2010
In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibitionDieter Gallemann, Elmar Wimmer, Constance C Höfer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 3, 2014
Time- and NADPH-dependent inhibition of cytochrome P450 3A4 by the cyclopentapeptide cilengitide: significance of the guanidine group and accompanying spectral changesMirza Bojić, Luca Barbero, Hugues Dolgos, et al.
Pharmacology Research & Perspectives|April 13, 2016
In vitro and in vivo drug disposition of cilengitide in animals and humanHugues Dolgos, Achim Freisleben, Elmar Wimmer, et al.
Clinical Pharmacology and Therapeutics|October 15, 2019
Evaluating the Role of Solubility in Oral Absorption of Poorly Water-Soluble Drugs Using Physiologically-Based Pharmacokinetic ModelingChristina Fink, Dajun Sun, Knut Wagner, et al.
Drug Metabolism Reviews|June 16, 2012
The right compound in the right assay at the right time: an integrated discovery DMPK strategyPeter Ballard, Patrick Brassil, Khanh H Bui, et al.
Drug Discovery Today|January 19, 2016
Translational Medicine Guide transforms drug development processes: the recent Merck experienceHugues Dolgos, Mark Trusheim, Dietmar Gross, et al.
Drug Discovery Today|April 7, 2020
Translational strategies in drug development for knee osteoarthritisKyra J Cowan, Kerstin Kleinschmidt-Dörr, Anne Gigout, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 13, 2018
A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug EvofosfamideChristian Lüpfert, Martin Dyroff, Oliver von Richter, et al.
Pageof 3